Update on Iti-007 Next Tuesday!

The Company’s presentations at SIRS will include:

Oral Presentation: “Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia: Efficacy Results from a Randomized, Double-Blind, Placebo-Controlled Trial,” will be presented by Kimberly E. Vanover, Ph.D., Senior Vice President of Clinical Development during the Clinical Trial Session on Tuesday, April 5th from 6:15 pm to 6:30 pm local time. Location: Affari, Lower Level

1 Like

It’s just a presentation next Tuesday, not the release of the drug…

Oh man, I thought that the drug was coming out next Tuesday! lol :smile: